Company: RPTX
Filing Date: 2025-06-02
Form Type: 8-K/A
Source: 0001193125-25-133312
Chunk: 1

Company: Repare Therapeutics Inc.
Filing Date: 2025-06-02
Form: 8-K/A
Chunk 1
---
 chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

<div align='center'>**EXPLANATORY NOTE**</div>

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

In connection with Ms. Alves’ appointment as the Company’s Senior Vice President, Chief Accounting Officer and principal accounting officer, the Company entered into an employment agreement with Ms. Alves on May 28, 2025 (the “Employment Agreement”). Pursuant to the Employment Agreement, Ms. Alves will initially receive an annual base salary of CA$350,000 and be eligible for an annual cash bonus with a target amount equal to 35% of her annual base salary.

The Employment Agreement further provides that, in the event that Ms. Alves’ employment is terminated by the Company without “cause” and not due to death or “disability” or she resigns for “good reason,” in each case, not in connection with a “change in control” (each term as defined in the Company’s 2020 Equity Incentive Plan (the “2020 Plan”)), then she shall be entitled to: (1) cash severance equal to seven months of base salary, paid in seven equal monthly installments; (2) continued participation in the Company’s group insurance plans and employee benefits for seven months; (3) accelerated vesting of her option awards and restricted stock unit awards that are subject to a time-based vesting schedule that were scheduled to vest in the six months following the date of termination, and Ms. Alves’ vested options shall remain exercisable for up to nine months following the date of such termination; and (4) any earned but unpaid annual bonus for the year immediately preceding the year in which her employment terminates. In lieu of the payments described in the preceding sentence, if within 90 days prior to or within 12 months following the execution of a definitive agreement for a change in control Ms. Alves is terminated by the Company (or a successor) involuntarily without “cause” and not due to death or “disability” or the executive resigns for “good reason,” then, she will be entitled to receive: (1) a lump-sum